clinical trial · NCT05768711
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
Groupe Francophone des Myelodysplasies·phase2·active not recruiting·n = 44
Chronic Myeloid LeukemiaVenetoclax
brief summary
Open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia
started
Oct 4, 2023
primary completion
Jun 16, 2026
completion
Oct 1, 2028
last updated
Sep 29, 2026
detailed description
AVENHIR trial is an open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of the combination of Azacitidine and Venetoclax in, hypomethylating agent-naïve, higher-risk chronic myelomonocytic leukemia patients
official title
Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol